siRNA Drug Cemdisiran Slashes Hospitalizations in Myasthenia Gravis Trial
A phase III trial shows cemdisiran, a complement-targeting siRNA, reduced myasthenic crises and hospital days by up to 92-fold vs placebo.
Summary
Cemdisiran, an investigational siRNA therapy that reduces complement component 5 (C5) production in the liver, dramatically cut hospitalizations and myasthenic crises in a phase III trial called NIMBLE. Compared to placebo, only 3.8% of cemdisiran-treated patients were hospitalized versus 15.3% on placebo. Total myasthenia gravis-related hospital days were just 1 in the treated group versus 92 in the placebo group over 24 weeks. The drug met its primary endpoint of improving daily-living scores, and rescue therapy use was also far lower in the treatment arm. Myasthenia gravis is a chronic autoimmune neuromuscular disease that worsens with age, making effective long-term management directly relevant to functional capacity and healthspan in older adults.
Detailed Summary
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by fluctuating muscle weakness that often worsens with age and can cause life-threatening respiratory crises. Effective therapies that reduce hospitalization and preserve functional independence are therefore directly relevant to healthspan and quality of life in aging populations.
A prespecified exploratory analysis of the phase III NIMBLE trial presented at the 2026 American Association of Neuromuscular and Electrodiagnostic Medicine meeting found that cemdisiran — a subcutaneous siRNA drug that silences complement component 5 (C5) production in the liver — sharply reduced hospitalizations. Only 3.8% of cemdisiran-treated patients were hospitalized for any reason during the 24-week double-blind period, versus 15.3% on placebo. Myasthenia gravis-related hospital days totaled just 1 in the treatment arm compared to 92 in the placebo arm, and only 3 treated patients experienced a myasthenic crisis versus 11 on placebo.
Cemdisiran also met the trial's primary endpoint: significant improvement in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at 24 weeks. Rescue therapy — an indicator of disease deterioration — was used by only 2 participants in the cemdisiran group versus 11 on placebo. The drug was generally well tolerated; the most common adverse event was upper respiratory tract infection, and no serious or meningococcal infections occurred during the blinded period.
NIMBLE participants had a mean age of around 50–54 years and roughly 95% carried anti-acetylcholine receptor antibodies, the hallmark of generalized MG. The findings suggest meaningful clinical benefit is achievable without complete complement blockade, potentially offering a more targeted and safer therapeutic approach than existing options.
Caveats include the exploratory nature of the hospitalization analysis, the relatively small sample sizes (79 treated, 72 placebo), and one investigator-flagged treatment-related death from pneumonia occurring after the blinded period. Larger, longer studies are needed to confirm durability and long-term safety.
Key Findings
- Cemdisiran reduced any-cause hospitalization rate to 3.8% versus 15.3% on placebo over 24 weeks.
- MG-related hospital days were 1 in the treated group versus 92 in the placebo group — a 92-fold difference.
- Only 3 treated patients experienced a myasthenic crisis compared with 11 on placebo.
- Rescue therapy use was cut from 11 patients on placebo to just 2 on cemdisiran.
- Benefits occurred without complete complement blockade, suggesting partial C5 suppression is clinically meaningful.
Methodology
This is a conference news report covering a prespecified exploratory analysis of the phase III NIMBLE randomized controlled trial, presented at a major neurology subspecialty meeting. The source, MedPage Today, is a credible medical news outlet; however, the full peer-reviewed publication has not yet been cited. The hospitalization analysis was exploratory and descriptive, not powered as a primary endpoint.
Study Limitations
The hospitalization analysis was a prespecified exploratory endpoint, not the primary endpoint, so it is hypothesis-generating rather than confirmatory. Sample sizes were modest (79 vs 72) and the 24-week follow-up period limits conclusions about long-term safety and durability. One possible treatment-related death post-trial warrants close scrutiny in future larger studies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: